Company research / VERU

Veru Inc. (VERU)

SEC name VERU INC. · CIK 0000863894 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated WI
  • Fiscal year ends Sep 30

Key ratios (year ended 2025-09-30)

-124.0%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-08

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-10, first reflected in a filing dated 2025-08-12. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-09-302024-09-302023-09-302023-06-302023-03-312022-12-312022-09-302021-09-302020-09-302019-09-30
Revenuen/an/a$16.89M$16.30Mn/an/an/a$39.35M$61.26M$42.59M$31.80M
Cost of Revenuen/an/a$11.03M$8.73Mn/an/an/a$8.76M$13.33M$11.81M$10.15M
Gross Profitn/an/a$5.85M$7.57Mn/an/an/a$30.59M$47.93M$30.79M$21.66M
R&D Expense$11.76M$15.59M$12.78M$51.20Mn/an/an/a$70.91M$32.69M$16.94M$13.74M
Operating Income-$19.19M-$24.75M-$36.17M-$93.78Mn/an/an/a-$83.49M$12.97M-$14.75M-$6.44M
Depreciation & Amortization$113.2K$152.1K$268.2K$269.9Kn/an/an/an/an/an/an/a
EBITDA-$19.08M-$24.60M-$35.90M-$93.51Mn/an/an/an/an/an/an/a
Net Income-$13.61M-$22.73M-$37.80M-$93.15Mn/an/an/a-$84.04M$7.39M-$18.97M-$12.02M
EPS (Diluted)n/an/an/a-$1.10n/an/an/a-$1.05$0.09-$0.28n/a
Total Assets$37.03M$29.84M$60.42M$50.02M$60.20M$70.34M$101.27M$135.36M$178.15M$51.54M$53.63M
Total Liabilities$8.65M$11.50M$28.10M$30.34M$39.56M$48.53M$52.08M$52.56M$25.85M$21.43M$21.30M
Shareholders' Equity$28.38M$18.33M$32.32M$19.68M$20.65M$21.81M$49.19M$82.80M$152.29M$30.11M$32.33M
Cash & Equivalents$23.88M$15.79M$24.92M$9.63Mn/an/an/an/an/an/an/a
Operating Cash Flow-$26.04M-$30.04M-$21.68M-$88.01Mn/an/an/a-$47.51M-$15.57M-$1.93M-$5.49M
Capital Expenditures$0$1.1K$158.3K$665.7Kn/an/an/a$733.1K$376.6K$105.8K$108.5K
Free Cash Flow-$26.04M-$30.04M-$21.84M-$88.68Mn/an/an/a-$48.24M-$15.95M-$2.04M-$5.59M
Shares Outstanding17.05M14.65M14.64M91.78Mn/an/an/a80.51M79.97M69.86M65.04M
Weighted Average Diluted Sharesn/an/an/a84.97Mn/an/an/a80.12M83.80M66.75Mn/a
EPS (Basic)n/a-$1.55-$2.80-$1.10n/an/an/a-$1.05$0.10-$0.28n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView